BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp continued to hold its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 111,905 shares of the company’s stock at the end of the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Teva Pharmaceutical Industries Limited were worth $3,717,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Ridgewood Investments LLC raised its stake in shares of Teva Pharmaceutical Industries Limited by 9.6% in the second quarter. Ridgewood Investments LLC now owns 8,837 shares of the company’s stock worth $294,000 after buying an additional 774 shares during the last quarter. Advisors Asset Management Inc. increased its position in Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Advisors Asset Management Inc. now owns 33,430 shares of the company’s stock worth $1,111,000 after buying an additional 9,136 shares during the period. Wedbush Securities Inc. increased its position in Teva Pharmaceutical Industries Limited by 30.8% in the second quarter. Wedbush Securities Inc. now owns 72,147 shares of the company’s stock worth $2,397,000 after buying an additional 16,980 shares during the period. DekaBank Deutsche Girozentrale increased its position in Teva Pharmaceutical Industries Limited by 7.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 404,288 shares of the company’s stock worth $13,294,000 after buying an additional 27,094 shares during the period. Finally, First Trust Advisors LP increased its position in Teva Pharmaceutical Industries Limited by 10.5% in the second quarter. First Trust Advisors LP now owns 612,724 shares of the company’s stock worth $20,355,000 after buying an additional 58,414 shares during the period. 56.04% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 16.49 on Thursday. The company’s 50-day moving average price is $26.26 and its 200 day moving average price is $30.58. Teva Pharmaceutical Industries Limited has a one year low of $16.45 and a one year high of $52.66. The company’s market cap is $16.75 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the firm earned $1.25 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -14.22%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/24/teva-pharmaceutical-industries-limited-teva-position-maintained-by-british-columbia-investment-management-corp.html.

TEVA has been the subject of a number of research reports. Vetr downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and set a $32.72 price target for the company. in a research note on Monday, May 1st. Wells Fargo & Company reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Saturday, April 29th. Maxim Group set a $35.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Thursday, May 11th. Deutsche Bank AG decreased their price target on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, May 12th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $38.00 price target (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. Four investment analysts have rated the stock with a sell rating, twenty have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average target price of $36.14.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.